Scott Sutherland, MD
Pediatric Medicine · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Lpch Medical Group Div of Lucile · 332 clinicians in this group
Hospitals listed: Lucile Salter Packard Children'S Hsp at Stanford. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Sutherland’s office at (650) 498-7200 to ask if they take your plan before you enroll.
California Medical Board record
Licence A83954 · Current
Licensed to practise in California · since 2003 · expires 2027-04-30 · Yale University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Lucile Salter Packard Children'S Hsp at StanfordPalo Alto, CAChildren · Voluntary non-profit - Private · No emergency departmentPart of Stanford Health Care, which runs 3 hospitalsNo overall ratingNo measure marked better or worse than the national rate
Original Medicare doctor bills
$10,229
Medicare paid this office $10,229 for 17 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $4,134 | $106 |
Who their Medicare patients are
17 Original Medicare patients in 2024. Average age 14 · Under 65 100% · 85 and older 0% · Health risk score 7.79. Sicker patients than 9 in 10 peers; the typical pediatric medicine clinician is at 1.4.
Conditions among them: High blood pressure 75% · Chronic kidney disease 75%.
The office billed $41,598, Medicare allowed $12,854 and paid $10,229; for 65 services of 8 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 17 | 65 | 14 | 7.79 | $41,598 | $10,229 |
| 2021 | 11 | 60 | 15 | 6.65 | $46,501 | $12,250 |
| 2020 | 12 | 71 | 13 | 7.59 | $62,644 | $14,808 |
| 2019 | 15 | 54 | 12 | 4.67 | $52,726 | $13,592 |
| 2018 | 12 | 38 | 13 | 5.31 | $27,587 | $7,438 |
| 2017 | 17 | 45 | 12 | 7.55 | $35,372 | $10,171 |
| 2016 | 27 | 100 | 15 | 5.96 | $55,047 | $17,085 |
| 2015 | 22 | 74 | 14 | 6.42 | $35,982 | $12,340 |
| 2014 | 14 | 68 | 12 | 6.19 | $44,267 | $13,800 |
| 2013 | 13 | 52 | 12 | 5.16 | $45,651 | $11,399 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2016: 1 service
| Long return visit (40+ min) | 14 | $3,675 | $111 |
2015: 1 service
| Long return visit (40+ min) | 14 | $3,021 | $126 |
Medicaid work
$15,874 in 2024
Medicaid paid $15,874 for 111 billed services this clinician did in 2024, up to 23 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 62 | $11,536 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 49 | $4,339 |
| 2024 | 111 | 2 | 23 | $15,874 |
| 2023 | 195 | 2 | 23 | $20,099 |
| 2022 | 79 | 2 | 21 | $9,018 |
| 2021 | 77 | 2 | 22 | $8,133 |
| 2020 | 45 | 1 | 14 | $3,946 |
| 2019 | 160 | 2 | 15 | $14,043 |
| 2018 | 128 | 2 | 15 | $9,218 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 98 | $13,144 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 97 | $6,955 |
2022
| Long return visit (40+ min) | 51 | $7,061 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 28 | $1,957 |
2021
| Long return visit (40+ min) | 50 | $6,331 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 27 | $1,803 |
2020
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 45 | $3,946 |
2019
| Long return visit (40+ min) | 70 | $7,693 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 90 | $6,350 |
2018
| Long return visit (40+ min) | 52 | $5,375 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 76 | $3,843 |
Money from drug and device companies
$5,000 in 2023
| 2023 | 1 | 1 | $5,000 | $5,000 |
| 2020 | 1 | 1 | $600 | $600 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Medtronic | Carpediem | $5,000 | 1 payment
|
See the published payment
| Medtronic | Paid to speak or teach · 2023-05-22 | Carpediem | $5,000 |
See earlier years (2020)
2020: $600
| CHF Solutions | Aquadex | $600 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Hoffmann-La Roche Limited · Efficacy Safety of Obinutuzumab Vs Mmf in Patients With Idiopathic Nephrotic Syndrome · 2025 | Their institution | $64,675 |
| ABBVIE INC. · A Study To Evaluate Safety Efficacy and Pharmacokinetics of Paricalcitol for Treatment of Secondary Hyperparathyroidism (Shpt) in Pediatric Participants With Stage 5 Chronic Kidney Disease (Ckd) · 2025 | Their institution | $54,714 |
| Bayer Healthcare Pharmaceuticals Inc. · Bay 948862, A 6-Month Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy, Safety and Pk/Pd of An Age-and Body Weight-Adjusted Oral Finerenone Regimen, in Addition To An Acei Or Arb, for the Treatment of Children, 6 Mo · 2024 | Their institution | $45,657 |
| Bayer Healthcare Pharmaceuticals Inc. · Finerenone Paediatric Ckd Trial · 2023 | Their institution | $42,816 |
| ABBVIE INC. · A Study To Evaluate Safety Efficacy and Pharmacokinetics of Paricalcitol for Treatment of Secondary Hyperparathyroidism (Shpt) in Pediatric Participants With Stage 5 Chronic Kidney Disease (Ckd) · 2024 | Their institution | $42,031 |
| BAXTER HEALTHCARE · Clinical Evaluation of the Prismaflex Hf20 Set and Prismaflex System 7.10 for Acute Crrt in Children · 2019 | Their institution | $41,723 |
| Hoffmann-La Roche Limited · Efficacy Safety of Obinutuzumab Vs Mmf in Patients With Idiopathic Nephrotic Syndrome · 2024 | Their institution | $31,222 |
| Hoffmann-La Roche Limited · Efficacy Safety of Obinutuzumab Vs Mmf in Patients With Idiopathic Nephrotic Syndrome · 2023 | Their institution | $24,115 |
| AKEBIA THERAPEUTICS INC · A Multicenter, Open-Label Study To Evaluate the Safety and Efficacy of Once Daily Oral Vadadustat for the Treatment of Pediatric Subjects With Anemia of Chronic Kidney Disease After Conversion From An Erythropoiesis-Stimulating Agent · 2022 | Their institution | $4,039 |
| AKEBIA THERAPEUTICS INC · A Multicenter, Open-Label Study To Evaluate the Safety and Efficacy of Once Daily Oral Vadadustat for the Treatment of Pediatric Subjects With Anemia of Chronic Kidney Disease Naive To Erythropoiesis-Stimulating Agents · 2022 | Their institution | $4,038 |
| ABBVIE INC. · M11-617 - A Study To Evaluate Safety Efficacy and Pharmacokinetics of Paricalcitol for Treatment of Secondary Hyperparathyroidism (Shpt) in Pediatric Participants With Stage 5 Chronic Kidney Disease (Ckd) · 2025 | Their institution | $3,388 |
Professional record
- NPI
- 1518027291
- Licence
- CA A83954California A83954: Current · expires 2027-04-30
- Trained
- Yale University School of Medicine, 2002
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A839540
- Taxonomy
- Federal specialty code 2080P0210X (2080P0210X); Pediatrics (208000000X)
- Mailing address
- 725 Welch Rd, Palo Alto, CA, 94304
- NPI first listed
- 2006-12-11
- NPI last updated
- 2024-07-01
- NPI record certified
- 2024-07-01
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 300 Pasteur Dr, Stanford, CA, 94305